Briacell Therapeutics Corp (BCTX) - Total Assets
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) holds total assets worth $27.07 Million USD as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Briacell Therapeutics Corp cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Briacell Therapeutics Corp - Total Assets Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's total assets have evolved over time, based on quarterly financial data. See Briacell Therapeutics Corp (BCTX) net assets for net asset value and shareholders' equity analysis.
Briacell Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (July 2025)
Briacell Therapeutics Corp's total assets of $27.07 Million consist of 92.0% current assets and 8.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.5% |
| Accounts Receivable | $776.54K | 2.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $253.71K | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Briacell Therapeutics Corp (BCTX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Briacell Therapeutics Corp's current assets represent 92.0% of total assets in 2025, an increase from 91.7% in 2006.
- Cash Position: Cash and equivalents constituted 48.5% of total assets in 2025, down from 91.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
Briacell Therapeutics Corp Competitors by Total Assets
Key competitors of Briacell Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Briacell Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.07 | 3.41 | 103.81 |
| Quick Ratio | 7.07 | 3.41 | 103.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.80 Million | $14.44 Million | $71.54 Million |
Briacell Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Briacell Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 1.01 |
| Asset Growth Rate (YoY) | 265.1% |
| Total Assets | $29.77 Million |
| Market Capitalization | $29.93 Million USD |
Valuation Analysis
Above Book Valuation: The market values Briacell Therapeutics Corp's assets above their book value (1.01x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Briacell Therapeutics Corp's assets grew by 265.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual total assets of Briacell Therapeutics Corp from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | $29.77 Million | +265.14% |
| 2024-07-31 | $8.15 Million | -77.53% |
| 2023-07-31 | $36.28 Million | -33.56% |
| 2022-07-31 | $54.60 Million | -24.73% |
| 2021-07-31 | $72.54 Million | +13787.95% |
| 2020-07-31 | $522.33K | +17.47% |
| 2019-07-31 | $444.66K | -80.54% |
| 2018-07-31 | $2.28 Million | +39.66% |
| 2017-07-31 | $1.64 Million | +95.78% |
| 2016-07-31 | $835.70K | -34.52% |
| 2015-07-31 | $1.28 Million | +5238.13% |
| 2014-07-31 | $23.91K | -99.75% |
| 2013-07-31 | $9.41 Million | -8.82% |
| 2012-07-31 | $10.32 Million | -16.41% |
| 2011-07-31 | $12.35 Million | +738.57% |
| 2010-07-31 | $1.47 Million | +41.73% |
| 2009-07-31 | $1.04 Million | +172.75% |
| 2008-07-31 | $380.81K | -16.54% |
| 2007-07-31 | $456.29K | +373.56% |
| 2006-07-31 | $96.35K | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more